Erchonia Making Strides in the Korean Market

Fusion Marketplace Changes Healthcare Traveler Experience

Fusion Marketplace is a traveler-first driven platform giving healthcare professionals the power to make decisions in their careers that they haven't been able to in the past.

Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry’s key pillars of design and engineering, regulatory, clinical, and market access into a single-source solution.

Erchonia Corporation, the global leader in low-level laser technology (“3LT”), is announcing new strides in the Korean market, particularly with its Lunula Laser, which targets foot fungus non-thermally and non-invasively with low-level laser technology. Since bringing its first Lunula unit to Korea back in 2015, Erchonia has continued to grow its stake there, placing a total of 277 units to date throughout the country.

Photograph of Erchonia Lunula LaserThe Lunula Laser is backed by extensive clinical data that led to the U.S. FDA market-clearing the laser to provide clear nail growth in patients with onychomycosis. In a placebo-controlled, randomized, double-blind clinical trial, 89 percent of patients responded to treatment, seeing clear, healthy nail growth in as little as four, 12-minute treatments per foot.

After Erchonia secured U.S. market clearance for the Lunula Laser, Erchonia’s international partner, C.M. Blue, registered the Lunula in Korea as the first device to improve onychomycosis with a non-thermal, low-level laser. Thanks to Lunula’s clinical results and Erchonia’s patent, C.M. Blue received approval from the Ministry of Food and Drug Safety (MFDS) on July 24, 2017, and Lunula has been growing in popularity in Korea ever since.

“The Lunula has been a great success among our product lines,” says Hoon Cheol Kim, CEO & President of C.M. Blue. “It’s very helpful for patients to have a non-thermal, painless treatment, covered by insurance. Doctors also save time with an effective and comfortable procedure for patients. The mutual needs of both doctors and patients are met with Lunula.”

C.M. Blue Sales & Marketing Director Joo Ho Park is also continuing this momentum by securing the most influential doctors to speak at medical conferences in Korea, targeting major clinics, and supporting Lunula’s expansion with various marketing activities including blogging and advertising.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles